Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with Merkel cell carcinoma: A systematic review and meta-analysis

American Journal of Clinical Dermatology

Volumn 14, Issue 6, 2013, Pages 437-447

  Treglia, Giorgio ^a   Dabbagh Kakhki, Vahid Reza ^b   Giovanella, Luca ^a   Sadeghi, Ramin ^b  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GALLIUM 68;

CANCER PATIENT; CLINICAL EXAMINATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISTANT METASTASIS; GLUCOSE METABOLISM; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MERKEL CELL TUMOR; META ANALYSIS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUALITY CONTROL; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SYSTEMATIC REVIEW;

CARCINOMA, MERKEL CELL; FLUORODEOXYGLUCOSE F18; HUMANS; LIKELIHOOD FUNCTIONS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84890521546     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.1007/s40257-013-0040-x     Document Type: Review

References (26)

1. Senchenkov A, Moran SL. Merkel cell carcinoma: diagnosis, management, and outcomes. Plast Reconstr Surg. 2013;131:771-778e.
2. Allen PJ, Bowne WB, Jaques DP, et al. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol. 2005;23:2300-9.
3. Han SY, North JP, Canavan T, et al. Merkel cell carcinoma. Hematol Oncol Clin North Am. 2012;26:1351-74.
4. Howle JR, Hughes TM, Gebski V, et al. Merkel cell carcinoma: an Australian perspective and the importance of addressing the regional lymph nodes in clinically node-negative patients. J Am Acad Dermatol. 2012;67:33-40.
5. Enzenhofer E, Ubl P, Czerny C, et al. Imaging in patients with merkel cell carcinoma. J Skin Cancer. 2013;2013:973123.
6. Treglia G, Cason E, Fagioli G. Recent applications of nuclear medicine in diagnostics (first part). Ital J Med. 2010;4:84-91.
7. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:e1-34.
8. Oxford Center for Evidence-Based Medicine checklist for diagnostic studies appraisal. http://www.cebm.net/index.aspx?o-1025. Accessed 30 April 2013.
9. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34.
10. Zamora J, Abraira V, Muriel A, et al. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006;6:31.
11. Siva S, Byrne K, Seel M, et al. 18F-FDG PET provides high-impact and powerful prognostic stratification in the staging of merkel cell carcinoma: a 15-year institutional experience. J Nucl Med. 2013;. doi: 10.2967/jnumed.112. 116814.
12. Ibrahim SF, Ahronowitz I, McCalmont TH, et al. 18F-fluorodeoxyglucose positron emission tomography-computed tomography imaging in the management of merkel cell carcinoma: a single-institution retrospective study. Dermatol Surg. 2013;. doi: 10.1111/dsu.12246.
13. Hawryluk EB, O'Regan KN, Sheehy N, et al. Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: a study of 270 scans in 97 patients at the Dana-Farber/Brigham and Women's Cancer Center. J Am Acad Dermatol. 2013;68:592-9.
14. Colgan MB, Tarantola TI, Weaver AL, et al. The predictive value of imaging studies in evaluating regional lymph node involvement in Merkel cell carcinoma. J Am Acad Dermatol. 2012;67:1250-6.
15. Lu Y, Fleming SE, Fields RC, et al. Comparison of 18F-FDG PET/CT and 111In pentetreotide scan for detection of Merkel cell carcinoma. Clin Nucl Med. 2012;37:759-62.
16. Maury G, Dereure O, Du-Thanh A, et al. Interest of (18)F-FDG PET-CT scanning for staging and management of merkel cell carcinoma: a retrospective study of 15 patients. J Eur Acad Dermatol Venereol. 2011;25:1420-7.
17. Concannon R, Larcos GS, Veness M. The impact of (18)F-FDG PET-CT scanning for staging and management of Merkel cell carcinoma: results from Westmead Hospital, Sydney, Australia. J Am Acad Dermatol. 2010;62:76-84.
18. Peloschek P, Novotny C, Mueller-Mang C, et al. Diagnostic imaging in Merkel cell carcinoma: lessons to learn from 16 cases with correlation of sonography, CT, MRI and PET. Eur J Radiol. 2010;73:317-23.
19. Belhocine T, Pierard GE, Frühling J, et al. Clinical added-value of 18FDG PET in neuroendocrine-merkel cell carcinoma. Oncol Rep. 2006;16:347-52.
20. Iagaru A, Quon A, McDougall IR, et al. Merkel cell carcinoma: is there a role for 2-deoxy-2-[f-18]fluoro-d-glucose-positron emission tomography/computed tomography? Mol Imaging Biol. 2006;8:212-7.
21. Mirk P, Treglia G, Salsano M, et al. Comparison between F-fluorodeoxyglucose positron emission tomography and sentinel lymph node biopsy for regional lymph nodal staging in patients with melanoma: a review of the literature. Radiol Res Pract. 2011;2011:912504.
22. Treglia G, Castaldi P, Rufini V, et al. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine. 2012;42:80-7.
23. Treglia G, Sadeghi R. Meta-analyses and systematic reviews on PET and PET/CT in oncology: the state of the art. Clin Transl Imaging. 2013;1:73-5.
24. http://www.nccn.org/professionals/physician-gls/pdf/mcc.pdf. Accessed on 23 July 2013.
25. Ratib O. PET/MRI: a new era in multimodality molecular imaging. Clin Transl Imaging. 2013;1:5-10.
26. Pace L, Nicolai E, Aiello M, et al. Whole-body PET/MRI in oncology: current status and clinical applications. Clin Transl Imaging. 2013;1:31-44.